𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mismatch repair gene promoter methylation and expression in hydatidiform moles

✍ Scribed by Huaizeng Chen; Dafeng Ye; Xing Xie; Weiguo Lu; Changkun Zhu; Xiaodong Chen


Book ID
106079987
Publisher
Springer
Year
2004
Tongue
English
Weight
252 KB
Volume
272
Category
Article
ISSN
0003-9128

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Promoter methylation and expression of M
✍ JΓΆrg Felsberg; Niklas Thon; Sabina Eigenbrod; Bettina Hentschel; Michael C. Sabe πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 534 KB

## Abstract Epigenetic silencing of the O^6^‐methylguanine‐DNA methyltransferase (__MGMT__) gene promoter is associated with prolonged survival in glioblastoma patients treated with temozolomide (TMZ). We investigated whether glioblastoma recurrence is associated with changes in the promoter methyl

Mismatch repair gene expression defects
✍ John P. Geisler; Michael J. Goodheart; Anil K. Sood; Richard J. Holmes; Melanie πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 149 KB

## Abstract ## BACKGROUND hMLH1, the human MutL homologue, has been linked to microsatellite instability (MSI) in gastrointestinal tumors. However, to the authors' knowledge, the role of hMLH1, the other mismatch repair genes (MMR), and MSI in ovarian carcinoma has not been well defined. The purpo

Mismatch repair gene expression defects
✍ Tuya Pal; Rebecca Sutphen; Thomas Sellers πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 69 KB

## Cancer-Related Fatigue: Evolving Concepts in Evaluation and Treatment I n their otherwise excellent review of cancer-related fatigue, Stasi et al. 1 failed to discuss opioid-induced androgen deficiency (OPIAD), an extremely common and easily identified cause of fatigue in men with malignant dis

Promoter methylation blocks FES protein-
✍ Jonathan M. Shaffer; Thomas E. Smithgall πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 1014 KB

## Abstract The __FES__ locus encodes a unique nonreceptor protein‐tyrosine kinase (FES) traditionally viewed as a proto‐oncogene but more recently implicated as a tumor suppressor in colorectal cancer (CRC). Recent studies have demonstrated that while FES is expressed in normal colonic epithelium,